Dean Baker, Senior Economist at Center for Economic and Policy Research, pointed out that we need significant changes in our insurance providers before handing them the reins to a “Medicare Advantage For All” system – at the least changing them to non-profit insurers like in other countries. He also proposed more radical changes to bring down prices, like abolishing patent monopolies for new drugs.
“The way we pay for drugs now, it’s like paying firefighters to come to your house when your house is on fire,” said Baker.--Lown Institute A think tank advocating a radically better and uniquely American health system that overturns high-cost, low-value care
First, there is quite a useful data trail when you are curious about patents. The US Patent and Trademark Office (USPTO) is freely searchable but you will need to understand a bit of the underlying reference material.
In my work I am interested in the citation indexes. Think of prior art, "any evidence that your invention is already known" as bread crumbs on the trail. Relying on the published work of Torrance and West, All Patents Great and Small: A Big Data Network Approach to Valuation I characterize the value of a patent by using "relative positions of issued United States patents embedded within a comprehensive patent citation network".
A company, Patentfield, allows limited searches of patents/utility models for free (up to 100 records) or you can expand access for a monthly fee. This is only one approach and as your mileage may vary, you are free to develop a unique algorithm better suited to your data question.
The second is hypothesis generation by searching clusters of biotech filings based on citations within the patent framework. The size of the node indicates level of importance of the patent within the network.
We need to be mindful of the "artistry" of wide brush strokes in discussions of value, innovation, and who is truly profiting when the patient is left holding the bill.